L'intérêt à découvert pour Moderna donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Moderna. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Moderna (NASDAQ:MRNA) Stock, Rapport sur les intérêts à découvert

MODERNA INC

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Inc

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$50.00</td>
<td>$160.0K</td>
<td>4</td>
<td>2.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$70.00</td>
<td>$55.4K</td>
<td>372</td>
<td>500</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.3K</td>
<td>6.7K</td>
<td>302</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$310.00</td>
<td>$25.5K</td>
<td>8.7K</td>
<td>173</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$40.00</td>
<td>$25.8K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$37.00</td>
<td>$47.8K</td>
<td>839</td>
<td>114</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$690.00</td>
<td>$37.0K</td>
<td>212</td>
<td>33</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$77.50</td>
<td>$36.0K</td>
<td>1.4K</td>
<td>26</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$470.00</td>
<td>$32.8K</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$680.00</td>
<td>$124.6K</td>
<td>10</td>
<td>11</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding IRON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 2000 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $160.0K, with a price of $80.0 per contract. There were 4 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a call option sweep that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 241 contract(s) at a $70.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $55.4K, with a price of $230.0 per contract. There were 372 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 290 day(s) on January 16, 2026. This event was a transfer of 59 contract(s) at a $25.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $480.0 per contract. There were 6708 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 37 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $25.5K, with a price of $690.0 per contract. There were 8768 open contracts at this strike prior to today, and today 173 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on April 17, 2025. This event was a transfer of 150 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $170.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 108 day(s) on July 18, 2025. This event was a transfer of 90 contract(s) at a $37.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $47.8K, with a price of $532.0 per contract. There were 839 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 45 day(s) on May 16, 2025. Parties traded 30 contract(s) at a $690.00 strike. The total cost received by the writing party (or parties) was $37.0K, with a price of $1236.0 per contract. There were 212 open contracts at this strike prior to today, and today 33 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option trade with bearish sentiment. It expires in 290 day(s) on January 16, 2026. Parties traded 24 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $1500.0 per contract. There were 1454 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a call option trade that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $3280.0 per contract. There were 2 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a call option trade with bearish sentiment. It expires in 654 day(s) on January 15, 2027. Parties traded 11 contract(s) at a $680.00 strike. The total cost received by the writing party (or parties) was $124.6K, with a price of $11330.0 per contract. There were 10 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRON

MRNA

VRNA

10 Health Care Stocks With Whale Alerts In Today's Session

News

Politics

General

CVAC

NVAX

Trump Administration Health Agency Firings Include Staff Overseeing Bird Flu Response

U.S. markets continued to witness volatility on Monday as President Donald Trump&#8217;s <a href="https://www.benzinga.com/markets/equities/25/03/44554789/trumps-liberation-day-tariffs-could-fuel-inflation-after-16-trillion-fiscal-surge-lawrence-mcdonald-warns">&#8216;Liberation Day&#8217;</a> fast approaches, bringing a volley of tariffs across products, industries, allies, and adversaries. Leading analysts and experts have since urged the President to reconsider his trade policy stance.
What Happened: The market experienced another roller-coaster trading day, with the S&amp;P 500 (INDEXSP: .INX) up 0.6% at close after being down 1.7% in the morning. While this helps shave off some of its losses this quarter, it still marks the worst quarter for the index in two-and-a-half years, losing 4.6%.
The NASDAQ (INDEXNASDAQ: .IXIC) ended 0.1% lower after witnessing wild swings of nearly 3% between the highs and lows of the day, followed by the Dow Jones Industrial Average (INDEXDJX: .DJI) which closed with a 1% gain, after swerving 417 points to erase some initial losses. Both the indices are down for the quarter, with the NASDAQ losing 10.5% and the Dow Industrials 2.3%.
Among individual stocks, Discover Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) and Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) were among top gainers at 7.5% and 4.4%, respectively, while Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), Grail Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) were among the top laggards, down 9% and 5% during the day, respectively.
Similarly, major index futures were a mixed bag on Monday evening, with Dow Futures up 1%, S&amp;P 500 Futures up 0.55%, and Nasdaq 100 down 0.14%. All of this comes in response to the uncertain global political climate and in anticipation of a messy global trade war that could disrupt all industries.
See More: <a href="https://www.benzinga.com/markets/equities/25/03/44554789/trumps-liberation-day-tariffs-could-fuel-inflation-after-16-trillion-fiscal-surge-lawrence-mcdonald-warns">Tariffs, Inflation And Tumbling Markets: These 5 ETFs Thrived Amid Last Week&#8217;s Chaos</a>
Why It Matters: Such steep curves have become routine for U.S. markets over the past couple of weeks, and there are no signs of it stopping any time soon, with seemingly no end to the uncertain trade policies of the Trump Administration, filled with false starts and abrupt changes.
Popular market voices such as Jim Cramer, who ironically <a href="https://economictimes.indiatimes.com/news/international/us/big-support-for-donald-trump-jim-cramer-shocks-wall-street-with-pro-tariff-stance-slams-free-trade-its-cost-us-fortunes/articleshow/119766832.cms?from=mdr">came out in support of the tariffs last week</a>, saying &#8216;I am pro-tariff, absolutely, I hate free trade,&#8217; is nonetheless, critical of the way the President is approaching this matter, stating that the uncertainty is taking a toll on the markets and investors.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Was today one-off? Only if the President wants it to be
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1906863841600041176?ref_src=twsrc%5Etfw">April 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cramer <a href="https://x.com/jimcramer/status/1906863841600041176">took to Twitter</a> again last night, addressing the wild swings in the market saying &#8216;Was today one-off? Only if the President wants it to be.&#8217; This was quite clearly aimed at the Trump Administration, asking for more certainty and clarity on trade policies going forward.
Photo Courtesy: Shutterstock.com
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/news/management/25/03/44574393/ford-gm-executives-address-trump-tariffs-in-internal-memos-aimed-to-reassure-employees-report">Ford, GM Executives Address Trump Tariffs In Internal Memos Aimed To Reassure Employees: Report</a></li>
</ul>

Markets

Media

GRAL

IXIC

Jim Cramer Asks Trump To Take Stock As Markets Swing Again Ahead Of 'Liberation Day'

Editor&#8217;s Note: This story has been updated to correct an error where &#8220;Nasdaq 100&#8221; was mistakenly used instead of &#8220;Nasdaq.&#8221;
The stock market faced a challenging day as risk sentiment remained under pressure on Wall Street. The&nbsp;S&amp;P 500&nbsp;experienced a volatile session, hitting its lowest point in over six months before recovering some losses. The S&amp;P ended the day 0.5% higher at 5,611.85. Despite this, the index is on track for its worst month since September 2022, with a 7% decline in March. The Dow Jones Industrial Average was up 1% at 42,001.76 for the day.
Meanwhile, tech stocks struggled, with the Nasdaq dropping 0.14% for the day at 17,299.29 as semiconductor stocks weighed heavily on the sector.
These are the top stocks that gained the attention of retail traders and investors throughout the day.
Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
Nvidia&#8217;s stock fell 1.18% to close at $108.38, with an intraday high of $110.96 and a low of $103.65. The stock&#8217;s 52-week range is between $153.13 and $75.61. The company announced plans to invest billions in the U.S. supply chain over the next four years. CEO Jensen Huang stated that the investment is possible due to suppliers like&nbsp;<a href="https://www.benzinga.com/25/03/44567096/nvidia-to-invest-billions-in-u-s-supply-chain-as-tech-companies-commit-to-trumps-onshoring-pledge">Taiwan Semiconductor Manufacturing Company</a>&nbsp;and Foxconn.
Moderna, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)
Moderna&#8217;s shares tumbled 8.90% to $28.35, with a high of $28.95 and a low of $26.80, marking a new 52-week low. The decline followed a shakeup at the U.S. Food and Drug Administration, with&nbsp;<a href="https://www.benzinga.com/25/03/44562368/moderna-novavax-shares-are-tumbling-monday-whats-going-on">Peter Marks</a>&nbsp;resigning from his role at the FDA's Center for Biologics Evaluation and Research.
See Also:&nbsp;<a href="https://benzinga.com/markets/25/03/44556147/mark-cuban-warns-of-red-rural-recession-as-hundreds-of-small-town-maga-supporters-reportedly-lose-federal-jobs-their-finances-will-be-turned-upside-down" target="_blank" rel="noreferrer noopener">Mark Cuban Warns Of &#8216;Red Rural Recession&#8217; As Hundreds Of Small Town MAGA Supporters Reportedly Lose Federal Jobs &#8211; Benzinga</a>
Lucid Group, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)
Lucid&#8217;s stock rose 4.31% to $2.42, reaching a high of $2.44 and a low of $2.21. The 52-week range is $4.43 to $1.93. The increase came after bullish commentary from a company executive, who <a href="https://in.benzinga.com/25/03/44570246/whats-going-on-with-lucid-stock-today">noted</a> a "dramatic uptick" in orders from former&nbsp;Tesla Inc.&nbsp;customers.
Dominari Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>)
Dominari&#8217;s shares fell 16.32% to $4, with a high of $5.46 and a low of $3.84. The stock&#8217;s 52-week range is $13.58 to $0.83. The decline followed the announcement of a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://in.benzinga.com/trading-ideas/movers/25/03/44566377/whats-going-on-with-dominari-holdings-stock-monday">mining deal</a> with&nbsp;Hut 8 Corp&nbsp;and a registered direct offering.
Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s stock decreased by 1.67% to $259.16, with an intraday high of $260.56 and a low of $243.36. The 52-week range is $488.54 to $138.8. Despite challenges,&nbsp;Elon Musk&nbsp;remains optimistic about Tesla&#8217;s future, viewing the current situation as a <a href="https://in.benzinga.com/25/03/44557947/doge-blowback-aside-elon-musk-considers-tesla-a-solid-opportunity">buying opportunity</a>.
Image via Shutterstock
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Benzinga Edge Stock Rankings show Lucid with a 97th percentile growth score — curious how Tesla compares? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Find out here.</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="695" height="105" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38.png" alt="" class="wp-image-850215" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38.png 695w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38-300x45.png 300w" sizes="(max-width: 695px) 100vw, 695px" /></a></figure>
Read Next:&nbsp;
<ul>
<li><a href="https://benzinga.com/markets/asia/25/03/44516620/chinas-chagee-files-for-nasdaq-ipo-what-investors-need-to-know" target="_blank" rel="noreferrer noopener">China&#8217;s Chagee Files For US IPO; What Investors Need To Know </a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

$BTC

DOMH

LCID

NVDA

TSLA

Nvidia, Moderna, Lucid, Dominari Holdings, Tesla: Why These 5 Stocks Are On Investors' Radars Today (CORRECTED)

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 38 trades.
If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 30 are puts, for a total amount of $1,594,617 and 8, calls, for a total amount of $394,717.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.5 to $60.0 for Moderna over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $22.5 to $60.0 over the preceding 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743445834_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$33.15</td>
<td>$33.15</td>
<td>$33.15</td>
<td>$60.00</td>
<td>$198.9K</td>
<td>215</td>
<td align="right">49</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.3</td>
<td>$6.15</td>
<td>$6.3</td>
<td>$30.00</td>
<td>$126.0K</td>
<td>1.0K</td>
<td align="right">215</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$8.45</td>
<td>$7.45</td>
<td>$8.45</td>
<td>$30.00</td>
<td>$114.0K</td>
<td>195</td>
<td align="right">228</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.45</td>
<td>$14.65</td>
<td>$14.65</td>
<td>$40.00</td>
<td>$84.9K</td>
<td>6.4K</td>
<td align="right">119</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$31.00</td>
<td>$83.3K</td>
<td>258</td>
<td align="right">199</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 15,324,366, the MRNA's price is down by -8.44%, now at $28.5. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 31 days.</li>
</ul>
<h3>Expert Opinions on Moderna</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $36.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $33. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $40.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Moderna's Options Frenzy: What You Need to Know

Risk sentiment remains under pressure at the start of the week on Wall Street, with tech-heavy indexes sliding while commodities advance, as traders fear a new wave of price pressures following <a href="https://www.benzinga.com/topic/tariffs">the upcoming tariffs announcement.</a>
The S&amp;P 500 experienced a turbulent morning session, first hitting its lowest level in over six months before clawing back some ground and trimming losses. Nevertheless, the benchmark equity index is on track for its worst month since September 2022, having fallen 7% in March.
Tech stocks remained the weakest link, with the Nasdaq 100 down 1.1% as semiconductor names weighed on the broader sector. The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) dropped 1.9% and is down 11.9% month-to-date — also marking its worst month since September 2022.
President Donald Trump's threats toward Iran over the weekend pushed crude oil prices up by 3.5% for the session, marking the biggest single-day gain since October.
Energy-related stocks outperformed and are on pace to log their fourth consecutive positive month, now up 8.5% year-to-date.
Meanwhile, gold prices continued to smash record highs, with bullion surging over 1% to $3,115 per ounce. Quarterly gains have reached 18% — the strongest three-month rally since 2009.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) inched up 1.2% to $83,400, fighting to avoid a second consecutive monthly decline.
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,688.45</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,555.01</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,001.35</td>
<td>-1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,075.33</td>
<td>-1.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.4% to $553.82.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.2% up to $416.59.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 1.1% to $463.82.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 0.9% to $198.50.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.5%; the&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) saw the worst performance, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Monday&#8217;s Stock Movers</h1>
<ul>
<li>Celsius Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) surged more than 7% after Truist upgraded the stock from Hold to Buy and lifted its price target from $35 to $45.</li>
<li>Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) roared 11% following a 52% drop on Friday. </li>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares plunged nearly 10% after the resignation of Dr. Peter Marks, the FDA's top vaccine official, sparked concerns over potential delays in the review of new treatments.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/etfs/25/03/44564323/tech-linked-etfs-suffer-outflows-in-march-as-ai-mini-bubble-pops-on-tariff-panic">Tech-Linked ETFs Suffer Outflows In March As AI &#8216;Mini Bubble&#8217; Pops On Tariff Panic</a></li>
</ul>
Photo: Shutterstock Professional via Shutterstock

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Econ #s

Tech

ETFs

CELH

SPDR Dow Jones Industrial Average ETF Trust

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

WOLF

Stocks Fall, S&P 500 Eyes Worst Month In Almost Two Years, Oil Rallies: What's Driving Markets Monday?

Vaccine stocks are trading lower Monday following a shakeup at the <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">U.S. Food and Drug Administration</a>.
What Happened: Peter Marks has resigned from his role at the FDA&#8217;s Center for Biologics Evaluation and Research. According to a Bloomberg<a href="https://www.bloomberg.com/news/articles/2025-03-31/vaccine-makers-plunge-after-fda-biologics-head-marks-steps-down?srnd=homepage-uk&amp;embedded-checkout=true"> report</a>, Marks was a top regulator at the FDA and played a key role in pushing quick approvals of vaccines during the Covid pandemic. 
Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares were down 13.5% at $26.88 and Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares were down 9.6% at $6.30 at last check. The SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) was down about 5.76% at publication time, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The report indicates that Marks was also responsible for the FDA&#8217;s evaluation of cutting-edge treatments like cell therapies and gene therapies. He reportedly cited some issues with Health and Human Services Secretary Robert F. Kennedy Jr. in his resignation letter.
"I was willing to work to address the Secretary's concerns regarding vaccine safety and transparency," Marks reportedly said in the letter. 
"However it has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies."
Check This Out: <a href="https://www.benzinga.com/25/03/44560524/auto-stocks-skid-after-trump-shrugs-off-higher-prices-should-you-buy-the-dip">Auto Stocks Skid After Trump Shrugs Off Higher Prices &#8211; Should You Buy The Dip?</a>
The news comes after vaccine stocks came under pressure last week following reports The Trump administration plans to end financial support for vaccine alliance Gavi, which helps buy vaccines for children in developing countries. The Trump administration reportedly plans to cut billions in global health initiatives. 
Moderna was awarded $590 million by the U.S. Department of Health and Human Services (HHS) in January to continue developing a vaccine to protect against bird flu. The Trump administration was reportedly&nbsp;<a href="https://www.benzinga.com/25/02/43999106/trumps-officials-to-re-consider-modernas-590-million-bird-flu-vaccine-funding-hhs-cites-biden-administrations-failed-oversight" target="_blank" rel="noreferrer noopener">reconsidering that funding</a>&nbsp;as of last month.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/insights/options/25/03/44518123/modernas-options-frenzy-what-you-need-to-know">Moderna&#8217;s Options Frenzy: What You Need to Know</a></li>
</ul>
Photo: Shutterstock.

Movers

Moderna, Novavax Shares Are Tumbling Monday: What's Going On?

Moderna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NYSE">MRNA</a>) short percent of float has risen 9.71% since its last report. The company recently reported that it has 46.88 million shares sold short, which is 16.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Moderna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743426018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Moderna has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Moderna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Moderna's peer group average for short interest as a percentage of float is 5.27%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Moderna's Recent Short Interest

mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19.

Moderna Secures Australian Therapeutic Goods Administration Approval For Respiratory Syncytial Virus Vaccine For Older Adults

Biotech

President Trump Says Will Be Announcing Pharma Tariffs Soon

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $1,051,700 and 2, calls, for a total amount of $85,619.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $70.0 for Moderna over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 4201.44 with a total volume of 3,894.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $25.0 to $70.0 over the last 30 days.
<h3>Moderna 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743089628_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.81</td>
<td>$30.00</td>
<td>$381.0K</td>
<td>3.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.81</td>
<td>$30.00</td>
<td>$381.0K</td>
<td>3.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$7.9</td>
<td>$7.85</td>
<td>$7.85</td>
<td>$35.00</td>
<td>$102.8K</td>
<td>6.7K</td>
<td>169</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.15</td>
<td>$5.05</td>
<td>$5.1</td>
<td>$35.00</td>
<td>$52.0K</td>
<td>2.6K</td>
<td>123</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.6</td>
<td>$2.59</td>
<td>$2.6</td>
<td>$25.00</td>
<td>$46.8K</td>
<td>6.6K</td>
<td>196</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Moderna</h3>
<ul>
<li>With a volume of 1,954,007, the price of MRNA is up 0.1% at $31.51. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $36.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup downgraded its action to Neutral with a price target of $40. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $33. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Vaccine makers Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) are facing selling pressure on Wednesday following reports suggesting the Trump administration will <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44495713/the-trump-administration-intends-to-terminate-u-s-financial-support-for-gavi-and-">end support for Gavi</a>.
What To Know: According to a New York Times <a href="https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html">report</a>, The Trump administration plans to cease financial support for vaccine alliance Gavi, which helps buy vaccines for children in developing countries. 
The Trump administration is also planning to &#8220;significantly scale back&#8221; support for efforts to combat malaria, the report states, citing a document from the United States Agency for International Development.
Meanwhile, the administration will continue to provide some grants for H.I.V. and tuberculosis medications, as well as food aid for countries in civil wars or facing natural disasters. In total, the Trump administration has reportedly decided to end 5,341 previously granted awards and continue with 898 of them. 
See Also: <a href="https://www.benzinga.com/insights/options/25/03/44422820/modernas-options-a-look-at-what-the-big-money-is-thinking">Moderna&#8217;s Options: A Look at What the Big Money is Thinking</a>
Funding for the United Nations Food and Agriculture Organization is also being terminated. The report indicates that the organization conducts surveillance for diseases that can be transmitted from animals to humans, including the bird flu. 
Moderna was awarded $590 million by the U.S. Department of Health and Human Services (HHS) in January to continue developing a vaccine to protect against bird flu. The Trump administration was reportedly <a href="https://www.benzinga.com/25/02/43999106/trumps-officials-to-re-consider-modernas-590-million-bird-flu-vaccine-funding-hhs-cites-biden-administrations-failed-oversight">reconsidering that funding</a> as of last month. 
MRNA, NVAX Price Action: At the time of publication, Moderna shares were down 5.70% at $31.91 and Novavax shares were down 3.37% at $7.30, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Global

Moderna, Novavax Shares Are Sliding Wednesday: What's Going On?

WIIM

BNTX

Shares of vaccine stocks are trading lower on reports suggesting the Trump Administration will end support for vaccine alliance, Gavi.

<a href="https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C" title="https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C">https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C</a>

Macro Economic Events

Economics

'The Trump Administration Intends To Terminate U.S. Financial Support For Gavi And To Significantly Scale Back Support For Efforts To Combat Malaria' - NY Times

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) shares dipped 15.38% after UBS downgraded the stock from Buy to Neutral and <a href="https://www.benzinga.com/quote/beke/analyst-ratings" target="_blank" rel="noreferrer noopener">announced a price forecast of $24.5</a>.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock fell 9.76%. The stock briefly surged after Google announced an expanded partnership with Reddit, aiming to integrate Reddit content more <a href="https://www.benzinga.com//node/44369039" target="_blank" rel="noreferrer noopener">effectively across Google's products</a>.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock dived 8.75% after reporting topline results from two Phase 3 clinical trials of Povorcitinib in <a href="https://www.benzinga.com//node/44356786" target="_blank" rel="noreferrer noopener">patients with Hidradenitis Suppurativa</a>. William Blair and Guggenheim downgraded the stock, and Truist Securities cut its <a href="https://www.benzinga.com/quote/incy/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $74 to $72</a>.</li>
<li>James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) shares decreased 8.39%.</li>
<li>XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares dipped 8.13% after the company reported a <a href="https://www.benzinga.com//node/44373548" target="_blank" rel="noreferrer noopener">fourth-quarter adjusted EPS miss</a>.</li>
<li>Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) shares decreased 7.63% after the company issued first-quarter adjusted<a href="https://www.benzinga.com//node/44426184" target="_blank" rel="noreferrer noopener"> EPS guidance below estimates</a>.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) stock fell 7.22%. The company said it is entering into a strategic partnership with Shield AI to deliver AI-powered autonomous solutions <a href="https://www.benzinga.com//node/44378015" target="_blank" rel="noreferrer noopener">for the U.S. government</a>.</li>
<li>Telus Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) shares decreased 7.07%.</li>
<li>Futu Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) stock declined 7.01%, probably after the People's Bank of China kept the one-year loan prime rate at 3.1% and the five-year rate at 3.6%. Policymakers are navigating how to support economic growth while stabilizing the yuan amid rising trade tensions.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares lost 6.02% last week after Rosenblatt cut its <a href="https://www.benzinga.com/quote/MU/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from</a> $250 to $200. The company reported <a href="https://www.benzinga.com//node/44425486" target="_blank" rel="noreferrer noopener">Q2 financial results</a>.</li>
</ol>
Image by Robert Way via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44450329/robinhood-roku-and-shopify-are-among-top-10-large-cap-gainers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?</a></li>
</ul>

Large Cap

BEKE

FUTU

INCY

RDDT

XPEV

XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

JP Morgan analyst Jessica Fye maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Underweight and lowers the price target from $40 to $33.

Price Target

Analyst Ratings

JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $33

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 10 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $977,910, and 2 were calls, valued at $135,544.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $150.0 for Moderna over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Moderna stands at 3553.6, with a total volume reaching 24,794.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $25.0 to $150.0, throughout the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742493702_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.75</td>
<td>$8.45</td>
<td>$8.5</td>
<td>$30.00</td>
<td>$579.7K</td>
<td>3.1K</td>
<td align="right">687</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.9</td>
<td>$45.00</td>
<td>$108.3K</td>
<td>7.5K</td>
<td align="right">357</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.47</td>
<td>$2.46</td>
<td>$2.47</td>
<td>$25.00</td>
<td>$87.4K</td>
<td>6.1K</td>
<td align="right">454</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.4</td>
<td>$4.35</td>
<td>$4.4</td>
<td>$35.00</td>
<td>$82.7K</td>
<td>816</td>
<td align="right">216</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.4</td>
<td>$5.35</td>
<td>$5.35</td>
<td>$35.00</td>
<td>$60.4K</td>
<td>7.6K</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 2,111,612, with MRNA's price up by 0.24%, positioned at $33.4.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 42 days.</li>
</ul>
<h3>Expert Opinions on Moderna</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $59.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Moderna, targeting a price of $78. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $40.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Moderna's Options: A Look at What the Big Money is Thinking

10 analysts have shared their evaluations of Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $57.1, a high estimate of $99.00, and a low estimate of $34.00. Highlighting a 30.27% decrease, the current average has fallen from the previous average price target of $81.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1741874592_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Moderna by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$78.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$34.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$51.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$99.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$108.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Moderna's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Moderna analyst ratings.</a>
<h2>Unveiling the Story Behind Moderna</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Financial Milestones: Moderna's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Moderna faced challenges, resulting in a decline of approximately -66.01% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Moderna's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -117.15%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Moderna's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.81%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Moderna's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.48%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Moderna adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Moderna Exec Says Co Expects "Little Bit More Of A Business As Usual" In Terms Of Vaccine-Related Meetings As Confirmations For Key Healthcare Roles Take Place

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 17 unusual trades.
Delving into the details, we found 47% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $295,190, and 11 were calls, valued at $528,166.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.5 to $140.0 for Moderna over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3103.07 with a total volume of 1,821.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $22.5 to $140.0 over the last 30 days.
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741630530_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$93.8</td>
<td>$93.35</td>
<td>$93.54</td>
<td>$130.00</td>
<td>$93.5K</td>
<td>12</td>
<td align="right">10</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.3</td>
<td>$6.05</td>
<td>$6.3</td>
<td>$40.00</td>
<td>$83.1K</td>
<td>2.1K</td>
<td align="right">154</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$9.0</td>
<td>$8.65</td>
<td>$9.0</td>
<td>$45.00</td>
<td>$81.9K</td>
<td>528</td>
<td align="right">91</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.35</td>
<td>$9.15</td>
<td>$9.35</td>
<td>$60.00</td>
<td>$73.8K</td>
<td>1.0K</td>
<td align="right">82</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$8.4</td>
<td>$8.0</td>
<td>$8.25</td>
<td>$45.00</td>
<td>$57.7K</td>
<td>2.9K</td>
<td align="right">128</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Moderna</h3>
<ul>
<li>Trading volume stands at 7,873,478, with MRNA's price up by 2.89%, positioned at $36.64.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 52 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $49.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Sector Perform with a new price target of $40. 
&#x2A; An analyst from B of A Securities has decided to maintain their Underperform rating on Moderna, which currently sits at a price target of $34. 
&#x2A; An analyst from Barclays has revised its rating downward to Equal-Weight, adjusting the price target to $45. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Moderna, which currently sits at a price target of $78. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding Moderna's Options Activity: What's the Big Picture?

Bird Flu Leads To Egg Shortages And Price Rise In America

Earnings

Press Releases

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health

Penny Stocks

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

Events

Moderna to Present at Upcoming Conferences in March 2025

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults

Contracts

Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease

AVTE

CTRX

DVAX

FHTX

HPTX

HZNP

SANA

TARS

ZNTL

ZSPH

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

JP Morgan

Citigroup

RBC Capital

Barclays

Screenshot 2024-04-30 at 5.36.02 PM

Health Care

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Comments

Moderna

Intérêt court

Moderna (NASDAQ:MRNA) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL